Yarrow Bioscience, Inc. 8K

VYNE Therapeutics Inc. approved and implemented a one-for-fifty reverse stock split of its common stock effective July 24, 2026, with cash paid in lieu of fractional shares.

VYNE Therapeutics Inc. filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to implement a one-for-fifty reverse stock split of its common stock, effective at 8:45 a.m. Eastern Daylight Time on July 24, 2026. At the effective time, every fifty shares of issued and outstanding (including treasury) common stock will be reclassified and combined into one share, with the par value per share remaining $0.0001. No fractional shares will be issued; instead, stockholders entitled to a fractional share after aggregation of their holdings will receive a cash payment equal to the fractional share multiplied by the closing trading price of the common stock on Nasdaq on the last trading day before the effective date (as adjusted for the split). Existing stock certificates and book-entry positions will automatically represent the post-split number of shares, and holders may surrender old certificates to receive new ones. The amendment was duly adopted under Delaware law by the company’s board of directors and stockholders and was executed on July 23, 2026 by Chief Executive Officer David Domzalski.

Filing Facts

CIK

1566044

Ticker

-

Form

8K

Source Type

sec

Accession

0001104659-26-087601

Alert Tier

6